Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
तुलना करने के लिए मीट्रिक्स | BTTX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधBTTXपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −0.8x | −0.6x | |
PEG अनुपात | 0.00 | −0.02 | 0.00 | |
क़ीमत/बुक | 0.0x | 0.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 1.0x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 14,900.0% | 51.3% | 58.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 33.1% | 8.8% | अनलॉक करें |